Composition, form of production and packaging
Eye drops 0.005% transparent, colorless.
latanoprost 50 Ојg
Excipients: sodium chloride 4.1 mg, sodium dihydrogen phosphate 4.6 mg, sodium hydrophosphate 4.74 mg, benzalkonium chloride 200 Ојg, purified water (up to 1 ml).
2.5 ml - a bottle-dropper polyethylene (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2012.
Antiglaucoma preparation, analogue of prostaglandin F 2? and a selective FP receptor agonist. Reduces intraocular pressure by increasing the outflow of watery moisture, mainly along the uveoscleral pathway. Does not have a significant effect on the production of aqueous humor and does not affect the hemato-ophthalmic barrier.
Decrease in intraocular pressure begins 3-4 hours after drug administration, maximum effect after 8-12 hours, the action lasts for at least 24 hours.
Suction and distribution
Well penetrates through the cornea, while hydrolysis occurs to the biologically active form.
Time to reach C max in aqueous humor - 2 h after topical application.
Metabolism and excretion
In the eye tissues, latanoprost acid is not practically metabolized; metabolism occurs mainly in the liver. The main metabolites - 1,2-dinor- and 1,2,3,4-tetranor metabolites do not possess or have weak biological activity.
T 1/2 - 17 min. It is excreted by the kidneys.
- open-angle glaucoma;
increased intraocular pressure.
In the conjunctival sac of the affected eye, one drop is injected 1 time / day, in the evening.
When skipping the dose, the next one is administered in the usual mode (i.e., the dose is not doubled).
From the side of the organ of vision: irritation of the eyes (burning sensation, sensation of sand in the eyes, itching, tingling and sensation of foreign body), blepharitis, conjunctival hyperemia, pain in the eyes, increased pigmentation of the iris, transient point erosions of the epithelium, edema of the eyelids, edema and erosion of the cornea , conjunctivitis, elongation, thickening, increase in the number and intensification of pigmentation of eyelashes and fleece hair, iritis / uveitis, keratitis, macular edema (including cystoid), changes in the direction of eyelash growth, sometimes causing eye irritation, blurring of vision.
Dermatological reactions: a rash, darkening of the eyelid skin and local skin reactions from the eyelids.
From the nervous system: dizziness, headache.
On the part of the respiratory system: bronchial asthma (including acute attacks or exacerbation of the disease in patients with bronchial asthma in the anamnesis), shortness of breath.
From the musculoskeletal system: pain in the muscles, pain in the joints.
Other: nonspecific chest pain.
- children and adolescence under 18;
- Hypersensitivity to the components of the drug.
With caution should be used in patients with aphakia, pseudoafacies with rupture of the posterior capsular lens, in patients with known risk factors for macular edema (in the treatment of latanoprost, cases of development of macular edema, including cystoid) are described; inflammatory, neovascular or congenital glaucoma (due to a lack of experience in the use of the drug).
PREGNANCY AND LACTATION
The use of latanoprost during pregnancy is possible only under the supervision of a doctor and only if the expected benefit for the mother exceeds the risk of developing possible side effects in the fetus.
Latanoprost and its metabolites can be excreted in breast milk. If you need Latanoprost during lactation, breastfeeding should be discontinued.
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
Causes a gradual change in eye color by increasing the amount of brown pigment in the iris. This effect is revealed mainly in patients with mixed iris color, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by the increase in melanin content in the stromal melanocytes of the iris.Usually, brown pigmentation spreads concentrically around the pupil to the periphery of the iris of the eyes, while the entire iris or parts of it can acquire a more intense brown color. In the case of an intense change in eye pigmentation, therapy is discontinued.
Patients with uniformly colored eyes of blue, gray, green or brown color change eye color after 2 years of use of the drug are very rare. The developed color change can be irreversible. Before starting treatment, patients should be informed about the possibility of changing eye color.
Latanoprost can cause gradual changes in eyelashes and fleece hair, such as lengthening, thickening, increasing pigmentation, increasing the density and changing the direction of growth of the eyelashes. The eyelash changes are reversible and pass after the cessation of treatment.
Patients who apply drops to only one eye may develop heterochromia.
The drug contains benzalkonium chloride, which can be absorbed by contact lenses. Before instilling eye drops, contact lenses should be removed; You can insert the lenses only 15 minutes after instillation.
Impact on the ability to drive vehicles and manage mechanisms
Patients who, after the application of eye drops, have a transient fogging of vision, it is not recommended to drive vehicles or work with mechanisms until it is restored.
Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episcler.
Treatment: symptomatic therapy.
Simultaneous instillation of two analogues of prostaglandins can cause a paradoxical increase in intraocular pressure.
When prescribing a combination therapy, eye drops of various drugs should be injected with an interval of at least 5 minutes.
Pharmaceutically incompatible with eye drops containing thiomersal (precipitation).
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, protected from light, at a temperature of 2 В° to 8 В° C; Do not freeze. Shelf life - 2 years.
The vial should be stored at a temperature of no higher than 25 В° C for 4 weeks.